Adding Venetoclax to Daratumumab and Dexamethasone in RRMM

In relapsed/refractory multiple myeloma, a recent study tested the addition of venetoclax to daratumumab and dexamethasone.


Saad Z. Usmani, MD: The combination of daratumumab with venetoclax and dexamethasone has been evaluated and reported on previously, primarily focusing on translocation (11;14) relapsed/refractory multiple myeloma. The initial dose-escalation study has previously been presented showing that this combination is very active for patients with translocation (11;14). At ASH [American Society of Hematology annual meeting] this year [2021], my colleague Jonathan Kaufman, [MD,] from Emory University had reported on the third part, which was a randomized phase 2 study part comparing venetoclax, daratumumab, dexamethasone to daratumumab, bortezomib, dexamethasone in patients with translocation (11;14). What he showed was a clear benefit in favor of the venetoclax, daratumumab, dexamethasone combination.

Now, this is a small randomized phase 2 study with a highly selected translocation (11;14) population. The safety profile looked tolerable. The responses were very high in favor of the venetoclax, daratumumab, dexamethasone combination. At the dose of 400 mg, I think the response rates were somewhere in the mid-70% range, whereas with the 800 mg dose of venetoclax, the responses were almost 100%. I’m excited about these data. I think we just need to see long-term follow-up to see if these responses are translating into PFS [progression-free survival] benefit for this patient population.

Transcript edited for clarity.

Related Videos
Yael Cohen, MD
Adam D. Cohen, MD, director, Myeloma Immunotherapy, associate professor in medicine, hematology/oncology, Abramson Cancer Center, University of Pennsylvania
Jeffery Zonder, MD
Natalie S. Callander, MD
Jeffery Zonder, MD
Susan Bal, MD
Michael J. Fallon, MD
Andrew Kin, MD
Marilena Tauro, PhD
Meera Mohan, MD, MS, FACP
Related Content